Fresenius Helios Gmbh entered into an agreement to acquire Boston IVF, LLP and Luarmia S.L. from NMC Health Plc (OTCPK:NMMC.F) and NMC Healthcare L.L.C. for an enterprise value of €430 million on December 21, 2020. The enterprise value includes approximately €80 million of minority interests and assumed debt. Pursuant to the terms, Fresenius Helios will acquire 100% stake in Luarmia S.L. and 70% stake in Boston IVF. The purchase price will be financed from existing cash and credit lines. In 2019, Luarmia and Boston IVF generated revenues of approximately €160 million and EBITDA of approximately €31 million. The transaction is subject to approval from relevant antitrust authorities. The transaction is expected to complete by the end of first half of 2021. The transaction is expected to be highly accretive to net income of Fresenius SE & Co. KGaA, parent of Fresenius Helios. Richard Fleming, Mark Firmin and Ben Cairns of Alvarez & Marsal Europe LLP acted as Joint Administrators of NMC Health and NMC Healthcare. Garousha, Khalid of Allen & Overy is serving as its legal advisor to NMC in connection with this transaction. John Fisher, Paul Humphreys and Javier Monzón of Freshfields Bruckhaus Deringer LLP acted as a legal advisor to Fresenius Helios Gmbh. KPMG Corporate Finance acted as financial advisor to Helios. Fresenius Helios Gmbh completed the acquisition of Boston IVF, LLP and Luarmia S.L. from NMC Health Plc (OTCPK:NMMC.F) and NMC Healthcare L.L.C. on April 14, 2021.